

## Atrial fibrillation as a marker of clinical severity in Brugada Syndrome

Autores: Nuno Cabanelas\*, MD; Elena Arbelo, MD, PhD; Paola Berne MD; José Maria Tolosana, MD; Antonio Berruezo, MD, PhD; Lluís Mont, MD, PhD, Ramon Brugada, MD, PhD; Josep Brugada MD, PhD

3) Instituição: Thorax Institute, Hospital Clinic, Barcelona, Spain; \*Hospital Distrital de Santarém

**Introduction:** Sodium channels dysfunction in Brugada Syndrome (BS) predisposes to ventricular arrhythmias. The same mechanism is thought to be also responsible for a higher predisposition to atrial arrhythmias. So, is hypothesized that atrial fibrillation (AF) may be part of clinical manifestations in BS patients, possibly associated with higher level of channel dysfunction.

**Aims:** To evaluate if documented AF episodes before BS diagnosis are associated with poorer prognosis, namely arrhythmic events and conduction cardiac system disease.

**Methods:** Prospective study. 278 patients with BS have been included. Two groups were established: A, with patients with documented AF episodes (previous or at the time of BS diagnosis) (n=14); and B, composed by those without documented AF episodes at the time of BS diagnosis (n=264). Syncope and ventricular tachycardia/fibrillation (VT/VF) events incidence during follow-up was evaluated, as well as cardiac conduction system disease incidence.

**Results:** Patients from group A were older ( $54.4 \pm 14.3$  vs  $43.1 \pm 14.0$ ,  $p=0.004$ ), and were more frequently the “proband” (100% vs 76.9%,  $p=0.045$ ). Mutations in gene SCN5A were identified in similar proportions (28.5% vs 21.6,  $p=ns$ ) among those who were genotyped. Previous syncope and episodes of VT/VF incidences were not significantly different at the time of inclusion (42.9% vs 20.8%,  $p=0.09$ ) and (7.1% vs 4.5%,  $p=ns$ ), respectively. End points incidences during a follow-up of  $59.3 \pm 49.4$  months are shown in table 1. At multivariate analysis, documented AF before BS diagnosis was an independent predictor of future syncope or VF/VT events

End-points incidence	Total (n=278)	Group A (n=14)	Group B (n=264)	p-value
Non vaso-vagal syncope	3.59%	14.3%	3.4%	0.09
VF/polymorphic VT	7.2%	28.6%	6.0%	0.012
Monomorphic VT	1.08%	0.0%	1.1%	ns
End-point (syncope + VT/VF)	11.87%	35.7%	10.6%	0.016
Death during follow-up	1.14%	0.0%	1.14%	ns
AF in follow-up	4.3%	21.4%	3.4%%	0.017

<b>Conduction system disease</b>	19.1%	42.9%	17.8%	0.032
AV block $\geq$ 1 <sup>st</sup> degree	11.2%	28.6%	10.2%	0.051
Average maximal PR duration (ms)		209.4 $\pm$ 53.7	189.8 $\pm$ 32.7	ns
Average maximal QRS duration (ms)		120.8 $\pm$ 29.1	110.7 $\pm$ 17.5	ns

**Conclusion:** Patients with documented AF before or at the time of BS diagnosis had higher incidence of a composed end-point of syncope and VT/VF episodes, as well as cardiac conduction system disease incidence. This facts support the hypothesis that AF can be a marker of higher degree of global sodium channel dysfunction and, consequently, more severe clinical manifestations.